These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 33429176

  • 1. Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results.
    Król B, Cywka KB, Skarżyńska MB, Skarżyński PH.
    Am J Otolaryngol; 2021; 42(2):102895. PubMed ID: 33429176
    [Abstract] [Full Text] [Related]

  • 2. Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients.
    Vos J, de Vey Mestdagh P, Colnot D, Borggreven P, Orelio C, Quak J.
    Eur Arch Otorhinolaryngol; 2017 Dec; 274(12):4121-4126. PubMed ID: 28956143
    [Abstract] [Full Text] [Related]

  • 3. Bioglass reconstruction of posterior meatal wall after canal wall down mastoidectomy.
    Sorour SS, Mohamed NN, Abdel Fattah MM, Elbary MEA, El-Anwar MW.
    Am J Otolaryngol; 2018 Dec; 39(3):282-285. PubMed ID: 29526381
    [Abstract] [Full Text] [Related]

  • 4. A technique for concurrent procedure of mastoid obliteration and meatoplasty after canal wall down mastoidectomy.
    Kim CW, Oh JI, Choi KY, Park SM, Park MI.
    Auris Nasus Larynx; 2012 Dec; 39(6):557-61. PubMed ID: 22321811
    [Abstract] [Full Text] [Related]

  • 5. Mastoid obliteration combined with soft-wall reconstruction of posterior ear canal.
    Takahashi H, Iwanaga T, Kaieda S, Fukuda T, Kumagami H, Takasaki K, Hasebe S, Funabiki K.
    Eur Arch Otorhinolaryngol; 2007 Aug; 264(8):867-71. PubMed ID: 17340129
    [Abstract] [Full Text] [Related]

  • 6. Mastoid Obliteration with Synthetic Materials: A Review of the Literature.
    Skoulakis C, Koltsidopoulos P, Iyer A, Kontorinis G.
    J Int Adv Otol; 2019 Dec; 15(3):400-404. PubMed ID: 31846919
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mastoid Obliteration Using S53P4 Bioactive Glass in Cholesteatoma Surgery: A 10-Year Single-Center Experience in 173 Adult Patients with Long-Term Magnetic Resonance Imaging Controlled Follow-up.
    Kroon VJ, Mes SW, Borggreven PA, van de Langenberg R, Colnot DR, Quak JJ.
    Otol Neurotol; 2022 Dec 01; 43(10):1181-1188. PubMed ID: 36099589
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tolerance and safety of 45S5 bioactive glass used in obliteration procedures during middle ear surgery: Preliminary results.
    Al Tamami N, Bawazeer N, Fieux M, Zaouche S, Tringali S.
    Am J Otolaryngol; 2020 Dec 01; 41(6):102542. PubMed ID: 32620365
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term results of canal wall reconstruction tympanomastoidectomy.
    Walker PC, Mowry SE, Hansen MR, Gantz BJ.
    Otol Neurotol; 2014 Jul 01; 35(6):954-60. PubMed ID: 25072070
    [Abstract] [Full Text] [Related]

  • 17. Canal wall down approach for tympano-mastoid cholesteatoma: long-term results and prognostic factors.
    Pareschi R, Lepera D, Nucci R.
    Acta Otorhinolaryngol Ital; 2019 Apr 01; 39(2):122-129. PubMed ID: 31097831
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.